Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017476323> ?p ?o ?g. }
- W2017476323 endingPage "604" @default.
- W2017476323 startingPage "597" @default.
- W2017476323 abstract "To analyze the in vivo biological effect of anti-interferon beta (IFN-beta) neutralizing antibodies (NABs), blood concentrations of neopterin, beta2microglobulin (Beta2-MG), mRNA-dependent myxovirusresistant protein A (MxA) and dsRNA-dependent protein kinase (PKR) were measured before (predose) and 24 hours after (postdose) IFN-beta administration in 49 patients with multiple sclerosis (MS) with (n = 25) and without (n = 24) NABs. The results indicated that predose levels of MxA-mRNA and PKR-mRNA were highly variable [coefficient of variation (CV) > 100%] among patients. A lower inter-individual variability was observed for pre-dose levels of Beta2-MG and neopterin (CVs of 29% and 44%, respectively). Significantly lower pre- and post-dose blood levels of IFN induced markers, except for postdose PKR-mRNA (p = 0.09), were seen in NAB+ compared with NAB–patients and between patients with high (> 200 t1/10) and low (£ 200 t1/10) NAB titers. A significant inverse correlation between NAB titer and pre-dose levels of the above IFN-induced markers was found. In summary, our findings confirm that NABs affect absolute concentrations of IFN-beta induced markers and suggest that such an effect occurs in a titer-dependent manner." @default.
- W2017476323 created "2016-06-24" @default.
- W2017476323 creator A5002559105 @default.
- W2017476323 creator A5013090680 @default.
- W2017476323 creator A5014279249 @default.
- W2017476323 creator A5023725739 @default.
- W2017476323 creator A5048477473 @default.
- W2017476323 creator A5053761865 @default.
- W2017476323 creator A5055098419 @default.
- W2017476323 creator A5064643117 @default.
- W2017476323 creator A5072939759 @default.
- W2017476323 creator A5073654164 @default.
- W2017476323 creator A5078446175 @default.
- W2017476323 date "2007-04-10" @default.
- W2017476323 modified "2023-09-27" @default.
- W2017476323 title "Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies" @default.
- W2017476323 cites W1574435394 @default.
- W2017476323 cites W1578501621 @default.
- W2017476323 cites W1964445903 @default.
- W2017476323 cites W1966221405 @default.
- W2017476323 cites W1973046191 @default.
- W2017476323 cites W1975995030 @default.
- W2017476323 cites W1978724534 @default.
- W2017476323 cites W1982833235 @default.
- W2017476323 cites W1983999022 @default.
- W2017476323 cites W1992753557 @default.
- W2017476323 cites W1993417921 @default.
- W2017476323 cites W1994918496 @default.
- W2017476323 cites W1997824576 @default.
- W2017476323 cites W1998359593 @default.
- W2017476323 cites W2005712402 @default.
- W2017476323 cites W2020275618 @default.
- W2017476323 cites W2020952837 @default.
- W2017476323 cites W2028974435 @default.
- W2017476323 cites W2029224047 @default.
- W2017476323 cites W2031490285 @default.
- W2017476323 cites W2039092164 @default.
- W2017476323 cites W2046354075 @default.
- W2017476323 cites W2047200592 @default.
- W2017476323 cites W2054010705 @default.
- W2017476323 cites W2055749608 @default.
- W2017476323 cites W2056736742 @default.
- W2017476323 cites W2061005334 @default.
- W2017476323 cites W2081404009 @default.
- W2017476323 cites W2086149172 @default.
- W2017476323 cites W2090002359 @default.
- W2017476323 cites W2093636733 @default.
- W2017476323 cites W2096569053 @default.
- W2017476323 cites W2104692290 @default.
- W2017476323 cites W2113298432 @default.
- W2017476323 cites W2126586565 @default.
- W2017476323 cites W2130355701 @default.
- W2017476323 cites W2137782187 @default.
- W2017476323 cites W2139367012 @default.
- W2017476323 cites W2144554627 @default.
- W2017476323 cites W2150466754 @default.
- W2017476323 cites W2159963451 @default.
- W2017476323 cites W2164542304 @default.
- W2017476323 cites W2169098250 @default.
- W2017476323 cites W2174908949 @default.
- W2017476323 cites W2312240793 @default.
- W2017476323 cites W2313649737 @default.
- W2017476323 cites W2335854897 @default.
- W2017476323 cites W2461811481 @default.
- W2017476323 cites W2485483395 @default.
- W2017476323 cites W2509277703 @default.
- W2017476323 cites W4243515193 @default.
- W2017476323 cites W4297966720 @default.
- W2017476323 cites W978779031 @default.
- W2017476323 doi "https://doi.org/10.1007/s00415-006-0332-7" @default.
- W2017476323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17420930" @default.
- W2017476323 hasPublicationYear "2007" @default.
- W2017476323 type Work @default.
- W2017476323 sameAs 2017476323 @default.
- W2017476323 citedByCount "23" @default.
- W2017476323 countsByYear W20174763232012 @default.
- W2017476323 countsByYear W20174763232013 @default.
- W2017476323 countsByYear W20174763232014 @default.
- W2017476323 countsByYear W20174763232015 @default.
- W2017476323 countsByYear W20174763232021 @default.
- W2017476323 crossrefType "journal-article" @default.
- W2017476323 hasAuthorship W2017476323A5002559105 @default.
- W2017476323 hasAuthorship W2017476323A5013090680 @default.
- W2017476323 hasAuthorship W2017476323A5014279249 @default.
- W2017476323 hasAuthorship W2017476323A5023725739 @default.
- W2017476323 hasAuthorship W2017476323A5048477473 @default.
- W2017476323 hasAuthorship W2017476323A5053761865 @default.
- W2017476323 hasAuthorship W2017476323A5055098419 @default.
- W2017476323 hasAuthorship W2017476323A5064643117 @default.
- W2017476323 hasAuthorship W2017476323A5072939759 @default.
- W2017476323 hasAuthorship W2017476323A5073654164 @default.
- W2017476323 hasAuthorship W2017476323A5078446175 @default.
- W2017476323 hasBestOaLocation W20174763232 @default.
- W2017476323 hasConcept C104317684 @default.
- W2017476323 hasConcept C105580179 @default.
- W2017476323 hasConcept C111113717 @default.
- W2017476323 hasConcept C112705442 @default.
- W2017476323 hasConcept C126322002 @default.